MBX Biosciences, Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.41M | -23.88M | -15.59M | -18.14M | -15.86M |
| Total Depreciation and Amortization | 61.00K | 77.00K | 58.00K | 75.00K | 63.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 998.00K | 525.00K | 118.00K | 632.00K | 505.00K |
| Change in Net Operating Assets | 918.00K | 600.00K | -627.00K | 2.77M | 2.02M |
| Cash from Operations | -17.43M | -22.68M | -16.04M | -14.66M | -13.27M |
| Capital Expenditure | -707.00K | -30.00K | -92.00K | -57.00K | -452.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.69M | 3.26M | -67.25M | -100.73M | -7.44M |
| Cash from Investing | 25.99M | 3.23M | -67.35M | -100.79M | -7.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.33M | 4.00K | 195.00K | 174.51M | 50.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 63.50M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -327.00K | -2.20M | -1.81M |
| Cash from Financing | 1.33M | 4.00K | -132.00K | 235.81M | -1.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.88M | -19.45M | -83.51M | 120.36M | -22.92M |